Original Article
circNFXI facilitates hepatocellular carcinoma progression by targeting miR-3064-5p/HMGA2 to enhance glutaminolysis

Erhui Xiao, Dongmei Zhang, Weili Zhan, Hui Yin, Li Ma, Junfeng Wei, Yi Kang, Zhongshan Mao

Department of Infectious Diseases, He’nan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of He’nan University, Zhengzhou, He’nan Province, China

Received January 15, 2021; Accepted May 14, 2021; Epub August 15, 2021; Published August 30, 2021

Abstract: Hepatocellular carcinoma (HCC) is acknowledged to be a fatal malignant cancer around the world. Circular RNAs (circRNAs) function as crucial regulators in the pathological procession of HCC. Here, we elucidated the biological function of a novel circRNA, circNFXI, in HCC tumorigenesis. qRT-PCR was performed to determine the expressions of circNFXI, miR-3064-5p, and HMGA2. circNFXI stability was evaluated after treatment with ribonuclease R. The growth and invasion of HCC cells were assessed by CCK8 and transwell assays. Protein levels were measured by Western blotting. The levels of glutaminolysis metabolites were evaluated by commercial kits. Dual-luciferase reporter assay, RNA immunoprecipitation (RIP) assay and RNA pull-down assay were performed for validating the interaction between miR-3064-5p and circNFXI/HMGA2. Tumor growth in vivo was detected using xenograft assay. Our results showed that circNFXI was remarkably up-regulated in HCC and was associated with a poor survival. Knockdown of circNFXI repressed proliferation, invasion and glutaminolysis of HCC cells. Moreover, circNFXI directly sponged miR-3064-5p to release HMGA2 expression, and thus conferred the malignant development of HCC. In conclusion, circNFXI serves as a competing endogenous RNA to accelerate HCC progression via regulating miR-3064-5p/HMGA2 axis, suggesting a therapeutic strategy for HCC intervention.

Keywords: Hepatocellular carcinoma, circNFXI, miR-3064-5p, HMGA2, glutaminolysis

Introduction

Hepatocellular carcinoma (HCC) has been regarded as the most common malignancy all over the world [1]. In China, due to the frequent hepatitis B virus infection and significant morbidity of liver cirrhosis, HCC is considered as one of the deadliest cancers [2]. In spite of effective treatments that have been defined, the prognosis is still poor over the last couple of years because of recurrence and metastasis [3]. Therefore, uncovering the pathogenesis is urgently needed for the diagnosis and treatment of HCC.

Circular RNAs (circRNAs), with a closed loop structure, represent a kind of non-coding RNAs. As compared with linear RNAs, circRNA have greater stability and can resist exonucleases-mediated digestion [4]. Recently, the regulation of circRNAs in tumorigenesis of multiple malignancies has been well documented. For example, circHECTD1 promoted gastric cancer development via sponging miR-1256 to enhance USP5 expression [5]. In HCC, hsa_circ_0004018 restrained malignant growth and metastasis via targeting miR-626/DKK3 axis to inhibit Wnt/β-catenin pathway [6]. CircNFXI (hsa_circ_0049658) has been verified to exert oncogenic roles in glioma [7] and non-small cell lung cancer [8]. However, the expression of circNFXI and its effect on HCC tumorigenesis have not been elucidated. Therefore, circNFXI is the focus in this study.

CircRNAs have been considered to control cancer development by acting as sponges for microRNAs (miRNAs) [9]. MiRNAs are another type of significant non-coding RNAs that repress gene expression via directly binding with 3’ untranslated region (3’-UTR) [10]. The regulation of miRNAs in carcinoma progression has been well accepted. miR-3064-5p expression was reduced in HCC, and an enforced expres-
Oncogenic role of circNFIX in hepatocellular carcinoma

Table 1. Oligonucleotide primer sets for qPCR

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence (5’-3’)</th>
<th>Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>circNFIX F</td>
<td>AGGAGATGCCGAGATCAAC</td>
<td>20</td>
</tr>
<tr>
<td>circNFIX R</td>
<td>GTGAAATACGGGCTCGACTG</td>
<td>20</td>
</tr>
<tr>
<td>NFIX F</td>
<td>TACCAGCGCGGTGATGAG</td>
<td>20</td>
</tr>
<tr>
<td>NFIX R</td>
<td>TGATGGTACAGCAAGATCCC</td>
<td>20</td>
</tr>
<tr>
<td>miR-3064-5p F</td>
<td>CTGCTGTGGTGTTGGTC</td>
<td>18</td>
</tr>
<tr>
<td>miR-3064-5p R</td>
<td>TGGTGTCGGAGAAGTC</td>
<td>16</td>
</tr>
<tr>
<td>U6 F</td>
<td>CTGCTGTGGTGTTGGTC</td>
<td>18</td>
</tr>
<tr>
<td>U6 R</td>
<td>AACGCTTACAGAATTGC</td>
<td>20</td>
</tr>
<tr>
<td>GAPDH F</td>
<td>ATCCCATCACACATCTCC</td>
<td>19</td>
</tr>
<tr>
<td>GAPDH R</td>
<td>CATCACGCACTACAGTCC</td>
<td>18</td>
</tr>
</tbody>
</table>

Expression of miR-3064-5p presented anti-angiogenic ability [11]. However, the upstream regulatory mechanisms of miR-3064-5p in HCC still need to be explored. Online databases predicted that circNFIX could bind to miR-3064-5p, thus we speculated that circNFIX might regulate HCC progression by targeting miR-3064-5p. Notably, bioinformatic analysis indicated that miR-3064-5p could bind to HMGA2. High mobility group A2 (HMGA2), an important transcription factor of high mobility group A family, regulates gene expression via modification of the chromatin architecture [12]. Mounting evidence has reported that dysregulation of HMGA2 participated in the development of a wide variety of tumors, including osteosarcoma [13], cutaneous squamous cell carcinoma [14], and lung adenocarcinoma [15]. HMGA2 has also been demonstrated to be up-regulated in HCC, which contributed to metastasis of HCC cells [16]. Therefore, the involvement of miR-3064-5p/HMGA2 axis in circNFIX-mediated biological functions in HCC needs to be elucidated.

In this study, the up-regulation of circNFIX was verified in HCC tissues. We further demonstrated that circHECTD1 facilitated HCC cell proliferation, invasion and glutaminolysis by targeting miR-3064-5p/HMGA2 axis, thus driving HCC progression. Our findings uncovered the biological roles of circRNA-miRNA-mRNA network in HCC, which may provide a novel therapeutic target for HCC.

Materials and methods

Clinical specimens

HCC and normal peritumor tissues (n=66) were obtained from He’nan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of He’nan University. All enrolled HCC patients signed written informed consent and did not receive radiotherapy or chemotherapy before surgery. This study was approved by the Ethics Committee of He’nan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of He’nan University (Approval No. Q/ZXYY-ZY-WB-LL201905201).

Cell lines and culture

Human HCC cell line Hep3B and normal hepatocyte cell line THLE-2 were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA), while HCC cell lines HuH7, MHCC97-H, and LM3 were obtained from Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All cells were maintained in high glucose dulbecco’s modified eagle medium (DMEM; BI, Hertzliya Pituach, Israel) with 10% fetal bovine serum (FBS) at 37°C with 5% CO₂.

Quantitative reverse transcription PCR (qRT-PCR)

To obtain nuclear and cytoplasmic fractions of HCC cells, a PARIS kit (Thermo Fisher, Franklin Lakes, MA, USA) was selected. Trizol (Thermo Fisher, Franklin Lakes, MA, USA) was used for total RNA purification. cDNA was prepared using PrimeScript RT Master Mix (TaKaRa, Tokyo, Japan). Subsequently, qRT-PCR was performed using the SYBR Premix Ex Taq™ (TaKaRa) with the MyIQ Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA) under the following conditions: an initial denaturation step for 10 min at 95°C and 40 amplification cycles comprising a denaturation step for 15 seconds at 95°C, an annealing step for 30 seconds at 60°C, and finally an elongation step for 30 seconds at 72°C. Relative RNA expression normalized to GAPDH or U6 was calculated by the 2⁻ΔΔCt. PCR primers are shown in Table 1.

Detection for circNFIX stability

Total RNA was incubated with ribonuclease R (RNase R) at 37°C for 1 h to evaluate circNFIX stability. After treatment, the expression of circNFIX and linear NFIX was assessed by qRT-PCR.
Cell transfection

Small interfering RNA (siRNA) for circNFIX (si-circNFIX), miR-3064-5p mimics and inhibitor were purchased from RIBOBIO (Guangzhou, China). HMG2 overexpression plasmid was obtained from Sino Biological (Beijing, China). The above fragments were transfected into HCC cells using Lipofectamine 3000 (Thermo Fisher) according to the instructions [17].

Cell counting kit-8 (CCK-8)

The HCC cells inoculated in 96-well plates were added with 10 μL CCK-8 solution (Abcam, Cambridge, UK). After incubation for 2 h, cell viability was detected at 450 nm using a microplate reader (Hidex, Turku, Finland).

Transwell assay

The invasion and migration of HCC cells were determined using Transwell chambers coated with or without Matrigel (BD, Franklin Lakes, NJ, USA). In brief, the suspension of HCC cells (containing 1×10^5 cells) was added to the upper chamber, while medium containing 10% FBS was added to the lower chamber. The residual cells in the upper chamber were removed after 48 h. The invading or migratory cells were stained with crystal violet and counted. The number of stained cells was counted in five random fields under a light microscope (Olympus, Tokyo, Japan).

Western blotting

Protein samples were acquired using radioimmunoprecipitation buffer (BioTeke Corporation, Beijing, China) and adjusted to the same concentration. Then, separation using sodium dodecyl sulfate-polyacrylamide gel electrophoresis was carried out. Afterwards, proteins were transferred onto polyvinylidene difluoride (PVDF) membranes, followed by probing with primary antibodies against Ki-67 (bs-23102R, 1:500, Bioss, Beijing, China), PCNA (bs-2007R, 1:1000, Bioss), ASCT2 (A6981, 1:1000, ABclonal, Wuhan, China), GLS1 (bs-10341R, 1:500, Bioss), HMG2 (A2972, 1:500, ABclonal), and β-actin (bs-0061R, 1:5000, Bioss) overnight at 4°C. Subsequently, the secondary antibody (bs-0369M-HRP, 1:5000, Bioss) was applied. An enhanced chemiluminescence reagent (En-green, Birkenhead, Auckland, New Zealand) was used for visualization of protein bands. The protein bands were quantified by densitometry using ImageJ software (NIH, Bethesda, MD, USA).

Xenograft transplantation in vivo

Female BALB/c nude mice (4 weeks old) were purchased from Slac Jingda Laboratory Animal Co., Ltd., Hunan, China. The HuH7 cells (1×10^7) stably transfected with sh-circNFIX or sh-NC were subcutaneously injected into the mice (n=6 per group). Tumor volume (mm^3) calculated as (width)^2 × length/2 was recorded every week. 5 weeks later, the mice were euthanized by pentobarbital overdose (210 mg/kg) and tumor weights were obtained. All animal procedures were approved by the Institutional Animal Care and Use Ethics Committee at the He’nan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of He’nan University and carried out according to the National Institutes of Health (NIH) guidelines for the ethical treatment of animals.

Prediction analysis

Online databases circAtlas (http://circatlas.biols.ac.cn/), circBank (http://www.circbank.cn/), and starBase (http://starbase.sysu.edu.cn/index.php) were adopted to predict the potential targets of circNFIX or miR-3064-5p.

Detection of glutamine, glutamate, and α-KG levels

The glutamine assay kit (Abcam), glutamate assay kit (Abcam), and alpha ketoglutarate (α-KG) assay kit (Abcam) were applied to detect glutamine, glutamate, and α-KG levels in HCC cells following the protocol booklets.

Dual-luciferase reporter assay

The wild type (WT) and mutant (MUT) sequences of circNFIX or HMG2 3’-UTR were subcloned into pGL3 vector (Promega, Madison, WI, USA). HCC cells were co-transfected with the above constructed WT or MUT plasmids together with miR-3064-5p mimics or mimics NC. After transfection for 48 h, luciferase signals were detected using a Dual Luciferase Reporter Gene Assay Kit (Yeasen, Shanghai, China).
Oncogenic role of circNFIX in hepatocellular carcinoma

RNA pull-down

The lysates of HCC cells were incubated with the biotinylated circNFIX (bio-circNFIX) or bio-NC for 2 h. Then, streptavidin magnetic beads (Thermo Fisher) were used for capturing RNAs complexes, followed by incubation with washing buffer containing proteinase K. miR-3064-5p level from bound RNAs was assessed by qRT-PCR.

RNA immunoprecipitation (RIP)

Magna RIP RNA-binding protein immunoprecipitation kit (Millipore, Bedford, MA, USA) was adopted for performing RIP assay. In short, HCC cells were subjected to RIP lysis buffer supplemented with protease and RNase inhibitors to prepare cell lysates. Incubation with magnetic beads with Ago-2 antibody or IgG antibody was carried out at 4°C overnight. Finally, the enrichment of circNFIX and miR-3064-5p in immunoprecipitated RNAs was evaluated by qRT-PCR.

Statistical analysis

The results are presented as mean ± standard deviation (±sd). Student’s t test for two group comparison or one-way ANOVA followed by Tukey post hoc test for multiple group comparison was performed using GraphPad prism 8.0, and P<0.05 was set for significant difference.

Results

circNFIX was up-regulated in HCC

First, circNFIX expression in 66 pairs of HCC tissue and normal peritumor tissue was determined by qRT-PCR. The results indicated that circNFIX was highly expressed in HCC samples in comparison to peritumor samples (Figure 1A). Furthermore, HCC patients with high circNFIX level presented lower overall survival rate as compared to those with low circNFIX level (Figure 1B). In line with the increased expression in HCC tissues, circNFIX was up-regulated in HCC cell lines, compared with normal hepatocyte cell line THLE-2 (Figure 1C). Moreover, RNase R degradation assay revealed that RNase R treatment led to reduced expression of linear transcript NFIX, whereas circNFIX level was not changed (Figure 1D). In Hep3B and HuH7 cells, nuclear mass separation assay indicated that circNFIX was mainly located in the cytoplasm (Figure 1E).

circNFIX depletion repressed HCC cell growth, migration and invasion

To address the function of circNFIX in HCC cell proliferation and metastasis, HCC cells (Hep3B and HuH7) with higher circNFIX expression were transfected with three si-RNAs targeting circNFIX. We found that circNFIX expression was remarkably decreased after transfection with all these three si-RNAs. The highest interference efficiency was found in si-circNFIX #1, which was selected in the subsequent experiments (Figure 2A). CCK8 assay showed that circNFIX silencing slowed down the proliferation of HCC cells (Figure 2B). Additionally, the migrative (Figure 2C) and invasive (Figure 2D) abilities were reduced in circNFIX-silenced HCC cells. Subsequently, the effect of circNFIX on HCC cell growth in vivo was evaluated in nude mice. As shown in Figure 2E, 2F, a smaller volume and weight of xenografts were observed after circNFIX depletion, as compared with sh-NC group. Western blotting analysis indicated that Ki-67 and PCNA protein levels in tumor tissues were reduced after knockdown of circNFIX (Figure 2G). Collectively, circNFIX down-regulation restrained the proliferation and motility of HCC cells.

circNFIX knockdown suppressed glutaminolysis of HCC cells

To further examine the regulation of circNFIX in glutaminolysis, a series of glutaminolysis metabolites were detected. As presented in Figure 3A-C, the levels of glutamine, glutamate and α-KG in HCC cells were evidently lowered by silencing circNFIX. In addition, the expression of glutaminolysis-related enzymes ASCT2 and GLS1 was assessed by Western blotting. ASCT2 and GLS1 are pivotal enzymes responsible for glutaminolysis [18, 19]. The protein levels of ASCT2 and GLS1 were significantly down-regulated in circNFIX-depleted HCC cells (Figure 3D). Therefore, circNFIX depletion inhibited glutaminolysis of HCC cells.

circNFIX binds to miR-3064-5p directly

To further investigate the downstream regulatory mechanism of circNFIX in HCC, three online databases including circBank, starBase and circAtlas were adopted to predict target
miRNAs of circNFIX. As presented in Figure 4A, miR-3064-5p was the only candidate according to the intersection results. Moreover, miR-3064-5p was distinctly down-regulated in HCC tissues in comparison to the adjacent tissues (Figure 4B). Accordingly, a negative correlation between circNFIX and miR-3064-5p in HCC tissues was verified (Figure 4C). Figure 4D showed the putative binding sites for miR-3064-5p in circNFIX. Subsequently, miR-3064-5p overexpression strikingly restrained the luciferase activity of circNFIX-WT in HCC cells, but did not change that of circNFIX-MUT (Figure 4E, 4F). Furthermore, RNA pull-down assay revealed that Bio-circNFIX probe resulted in a higher enrichment of miR-3064-5p in HCC cells (Figure 4G). Additionally, RIP assay demonstrated that the enrichment of circNFIX and miR-3064-5p was significantly promoted in Ago2 group, as compared with IgG group (Figure 4H). More importantly, knockdown of circNFIX led to higher miR-3064-5p level in HCC cells (Figure 4I). These data suggested that miR-3064-5p was a direct target of circNFIX.

circNFIX knockdown inhibited HCC progression via targeting miR-3064-5p

Next, we determined whether circNFIX regulated HCC development via miR-3064-5p by performing multiple rescue experiments. For this purpose, circNFIX-silenced HCC cells were fur-
Oncogenic role of circNFIX in hepatocellular carcinoma
Oncogenic role of circNFX in hepatocellular carcinoma

Figure 2. Down-regulation of circNFX repressed HCC cell proliferation and motility. A: qRT-PCR for assessing circNFX level in HCC cells transfected with si-circNFX; B: HCC cell proliferation after circNFX silencing was determined by CCK-8; C, D: The migration and invasion of HCC cells were evaluated by transwell assay (200×); E: The volume of xenograft tumors was measured once a week; F: Tumor weight was detected after the experiment; G: Protein levels of Ki-67 and PCNA in tumor tissues were assessed by Western blotting. **P<0.01; ***P<0.001.

Figure 3. Silencing circNFX restrains glutaminolysis of HCC cells. A-C: The levels of glutamine, glutamate, and α-KG in HCC cells after transfection with si-circNFX were detected by commercial kits; D: Western blotting for determining ASCT2 and GLS1 levels in HCC cells. ***P<0.001.

The decreased expression of miR-3064-5p in HCC induced by miR-3064-5p inhibitor was confirmed by qRT-PCR (Figure 5A). Functional assays demonstrated that miR-3064-5p inhibitor reversed the inhibitory effect of circNFX depletion on HCC cell growth (Figure 5B), migration and invasion (Figure 5C-E). Furthermore, inhibition of miR-3064-5p promoted glutaminolysis in circNFX-silenced HCC cells as evidenced by up-regulating levels of glutaminolysis metabolites glutamine, glutamate and α-KG (Figure 5F-H). Consistently, the decreased ASCT2 and GLS1 levels mediated by si-circNFX in HCC cells were restored by miR-3064-5p inhibitor (Figure 5I). Taken together, these observations indicated that circNFX/miR-3064-5p axis participated in the progression of HCC.

HMGA2 is a downstream target of circNFX/miR-3064-5p axis

We further explored the downstream effector of circNFX/miR-3064-5p axis. By bioinformatic analysis, HMGA2 was predicted as the target gene of miR-3064-5p and their complementary sequences are shown (Figure 6A). Further Dual-luciferase assay demonstrated that HMGA2 was the direct target gene of miR-3064-5p in HCC cells (Figure 6B). As assessed by Western blotting, HMGA2 protein level was down-regulated by miR-3064-5p overexpression, while up-regulated by miR-3064-5p suppression (Figure 6C, 6D). Furthermore, silencing of circNFX-mediated down-regulation of HMGA2 level was effectively counteracted by miR-3064-5p inhibitor (Figure 6E). These data suggested that circNFX regulated HMGA2 expression by targeting miR-3064-5p in HCC cells.

HMGA2 overexpression counteracted the antitumor effects of circNFX silencing on HCC cells

Finally, rescue experiments were carried out to assess the contribution of HMGA2 to circNFX/miR-3064-5p axis-mediated malignant process of HCC. As shown in Figure 7A, overexpression of HMGA2 in HCC cells was validated by Western blotting assay. In addition, si-circ-
Oncogenic role of circNFIX in hepatocellular carcinoma

Figure 4. circNFIX acted as a sponge for miR-3064-5p. A: Overlap of the predicted target miRNAs of circNFIX by circBank, starBase and circAtlas; B: qRT-PCR for detecting circNFIX level in HCC and normal tissues; C: Correlation analysis between circNFIX and miR-3064-5p expression in HCC tissues; D: Schematic illustration of the predicted complementary sequences for miR-3064-5p in circNFIX; E: Overexpression of miR-3064-5p in HCC cells was validated by qRT-PCR; F: Relative luciferase activity of HCC cells co-transfected with circNFIX-WT or MUT and miR-3064-5p mimics or mimics NC; G: RNA pull-down assay for evaluating the effect of miR-3064-5p enrichment on circNFIX; H: The recruitment of miR-3064-5p by circNFIX was confirmed by anti-Ago2 RIP assay; I: qRT-PCR for detecting miR-3064-5p expression in circNFIX-silence HCC cells. ***P<0.001.
Oncogenic role of circNFX in hepatocellular carcinoma

A

Hep3B

HuH7

Relative miR-3064-5p expression

NC inhibitor
miR-3064-5p inhibitor

Relative miR-3064-5p expression

NC inhibitor
si-circNFX

miR-3064-5p inhibitor

24 h 48 h 72 h

OD570nm Value

24 h 48 h 72 h

OD570nm Value

B

Hep3B

HuH7

si-NC
si-circNFX

miR-3064-5p inhibitor

si-NC
si-circNFX

miR-3064-5p inhibitor

C

Hep3B

si-NC
si-circNFX

Hep3B

si-circNFX

Hep3B

si-NC
si-circNFX

migration

Huh7

si-NC
si-circNFX

migration

Huh7

si-circNFX

migration

D

D

E

F

G

Hep3B

Huh7

Hep3B

Huh7

Migrated cell numbers

F

Hep3B

Huh7

Invaded cell numbers

Hep3B

Huh7

Relative glutamate level

Hep3B

Huh7

Relative α-KG level

Hep3B

Huh7

H

si-NC
si-circNFX

si-circNFX

si-circNFX

miR-3064-5p inhibitor

si-circNFX

miR-3064-5p inhibitor

Hep3B

Huh7

Relative protein expression

Hep3B

Huh7

Relative protein expression

Hep3B

Huh7

Relative protein expression

Hep3B

Huh7

Relative protein expression

Hep3B

Huh7

Relative protein expression
NFIX-induced decreases of proliferative, migratory, and invasive potencies of HCC cells were recovered by HMGA2 overexpression (Figure 7B-E). Moreover, enforced expression of HMGA2 reversed the reduced glutamine, glutamate, and α-KG in circNFIX-depleted HCC cells (Figure 7F-H). As expected, the declined expression of ASCT2 and GLS1 owing to circNFIX knockdown was abolished when HMGA2 was overexpressed in HCC cells (Figure 7I). These findings suggested that circNFIX/miR-3064-5p axis affected the growth, motility and glutaminolysis of HCC cells via HMGA2.

Discussion

HCC carries a really poor prognosis. A better interpretation of the pathological mechanisms of HCC tumorigenesis may be helpful for seeking effective therapeutic targets. It has been accepted that circRNAs can affect their target gene expression at transcriptional or post-transcriptional level and thus play pivotal biological functions in multiple diseases [20]. Mounting studies have reported that the dysregulation of circRNAs is implicated in the occurrence and development of HCC [21, 22]. In this study, a novel circRNA, circNFIX, was identified to be up-regulated in HCC tissues and cells. According to the results, Hep3B and HuH7 cells presented the highest circNFIX expression level among a series of HCC cells. Therefore, Hep3B and HuH7 cells were chosen for transfection with si-circNFIX and adopted in subsequent experiments. Moreover, knockdown of circNFIX repressed glutaminolysis to inhibit the proliferation and metastasis of HCC cells. Mechanistically, circNFIX was demonstrated to interact with miR-3064-5p to enhance HMGA2 expression. These findings implied that circNFIX might function as an oncogene to facilitate malignancy of HCC.
Oncogenic role of circNFIX in hepatocellular carcinoma

A

vector
HMGA2

HMGA2
β-actin

Hep3B
HuH7

Relative HMGA2 protein expression

B

Hep3B
HuH7

OD450nm Value

24 h 48 h 72 h

C

si-NC
si-circNFIX
si-circNFIX+HMGA2

Hep3B
HuH7

Migration

Invasion

D

E

si-NC
si-circNFIX
si-circNFIX+HMGA2

Hep3B
HuH7

Migrated cell numbers

Invaded cell numbers

F

G

H

I

si-NC
si-circNFIX
HMGA2
si-circNFIX+HMGA2

Hep3B
HuH7

Relative glutamine level

Relative α-KG level

Relative protein expression
Glutaminolysis has been recognized as an important hallmark in tumor-cell metabolism, which satisfies the bioenergetic needs for the survival and growth of cancer cells [23, 24]. The regulation of circRNAs in glutaminolysis during cancer development has been reported. For example, circHMGCS1 has been shown to promote the growth of hepatoblastoma cells via enhancing glutaminolysis [25]. Li et al. reveal that circGSK3B facilitated glutamine metabolism, which accelerated HCC progression [26]. In line with these studies, for the first time, this study also validated the regulation of circNFIX in glutaminolysis during HCC progression. We found that circNFIX reduced the levels of glutaminolysis metabolites and suppressed the expression of ASCT2 and GLS1 enzymes in HCC cells. Thus, glutaminolysis was involved in circNFIX-mediated HCC progression.

It has been widely known that circRNAs, distributed in cytoplasm, can act as sponge of miRNA to affect miRNA level. In human cancers, circRNAs may affect gene expression via sequestering miRNAs, possessing carcinogenic or anti-cancer roles [27]. For instance, Xu et al. suggested that circRNA_0000392 conferred tumorigenesis of colorectal cancer by serving as a sponge of miR-193a-5p [28]. A previous study indicated that circEYA1 drove cervical adenocarcinoma progression by sponging miR-582-3p [29]. In the present study, we demonstrated that circNFIX regulated the progression and glutaminolysis of HCC by targeting miR-3064-5p. The anti-tumor effects of miR-3064-5p have been confirmed in various cancers. As reported, miR-3064-5p inhibition reversed the anti-tumor action of si-circCOL6A3 in gastric cancer cells [30]. In addition, miR-3064-5p inhibition was involved in exosomal circPRRX1-mediated doxorubicin resistance during the advancement of gastric cancer [31]. In HCC, miR-3064-5p was reported to suppress angiogenesis and may be a target for HCC therapy [11]. Our results further verified the function of miR-3064-5p in HCC and showed that inhibition of miR-3064-5p overturned the suppressive effects of si-circNFIX on HCC cell proliferation, migration, invasion and glutaminolysis. Therefore, we concluded that circNFIX depletion slowed down HCC progression by up-regulating miR-3064-5p.

HMGA2 is invariably up-regulated in malignant tumors, which confers the development of many kinds of cancers, such as breast cancer [32], pancreatic cancer [33], colorectal cancer, and so on [34]. Hence, inhibition of HMGA2 may be a crucial therapeutic approach for cancer therapy. Zhao et al. revealed that inhibition of HMGA2 by siRNA-lipoplexes could suppress gastrointestinal cancer cell proliferation and motility [35]. Additionally, enhanced HMGA2 level was reported to correlate with poor prognosis of liver cancer cases [36]. Besides, a previous study showed that panobinostat-mediated HMGA2 suppression could restrain liver cancer cell growth in vitro and in vivo [37]. Our data first demonstrated that HMGA2 was a downstream target gene of miR-3064-5p, and HMGA2 protein level was enhanced by circNFIX-mediated miR-3064-5p inhibition in HCC cells. We also revealed that overexpression of HMGA2 abolished the inhibitory effect of circNFIX depletion on HCC cell malignant progression. Therefore, circNFIX acted as a regulator of HMGA2, and circNFIX/miR-3064-5p/HMGA2 axis played a pivotal role in HCC.

We are aware the fact that there are some limitations in this study. First, the small sample size may result in the statistical limitation of the study. Secondly, circNFIX can exert its function via ceRNA network, and this study only investigated the role of circNFIX/miR-3064-5p/HMGA2 axis. In the future study, more potential target miRNAs of circNFIX and their roles in HCC need to be explored. Also, future research needs to base upon large sample size.

Taken together, our findings suggested that the aberrant up-regulation of circNFIX in HCC tissues and cells could be a biomarker for HCC. In addition, down-regulation of circNFIX restrained HCC malignant progression via regulating miR-3064-5p/HMGA2 axis, uncovering a new mechanism for HCC development (Figure)
Oncogenic role of circNFIX in hepatocellular carcinoma

We suggest that circNFIX may be an effective therapeutic target for HCC patients in the future.

Disclosure of conflict of interest
None.

Address correspondence to: Zhongsan Mao, Department of Infectious Diseases, He’nan Provincial People’s Hospital, People’s Hospital of He’nan University, No. 7 Weiwu Road, Jinshui District, Zhengzhou 450003, He’nan Province, China. Tel: +86-0371-67129851; Fax: +86-0371-67129851; E-mail: maozhongshan66ds@163.com

References


Oncogenic role of circNFIX in hepatocellular carcinoma


